CLS Enters Research Agreement with US National Cancer Institute
CLS Enters Research Agreement with US National Cancer Institute
Clinical Laserthermia Systems AB (CLS) has announced a research agreement with the U.S. National Cancer Institute (NCI). The agreement extends CLS's non-sponsored collaboration through 2029.
Agreement Details
Under the agreement, CLS will conduct research on cancer treatment using its laser thermotherapy technology. The collaboration will include preclinical and clinical studies.
CLS's CEO stated, "This long-term collaboration with NCI demonstrates the potential of our technology. We aim to offer new treatment options for cancer patients."
About the Company
Clinical Laserthermia Systems AB is a medical technology company developing laser-based thermotherapy systems. The company's shares are traded on OMX Stockholm.
The news, analyses, and comments on this platform do not constitute investment advice. When making investment decisions, you should conduct your own research and consult with a qualified financial advisor if necessary. FiNews cannot be held responsible for any losses that may arise from the use of this information.
More Headlines
Tokyo Core Inflation Slows, Remains Below BOJ Target
Tokyo Core Inflation Slows, Remains Below BOJ Target
…Nikkei May Rise on Hopes for U.S.-Iran Peace Deal
Nikkei May Rise on Hopes for U.S.-Iran Peace Deal
…Australian Pension Fund HUB24 Faces Regulatory Scrutiny
Australian Pension Fund HUB24 Faces Regulatory Scrutiny
…